The treatment begins with the administration of doxycycline, an antibiotic taken orally. This medication is used to target and eradicate the Chlamydophila psittaci infection.

The dosage and frequency of doxycycline will be determined by the medical team based on individual patient needs. The duration of this initial treatment phase is prolonged to ensure effective eradication of the infection.

After the initial treatment phase, the patient’s response to the therapy is monitored. This involves regular check-ups and tests to assess whether the Chlamydophila psittaci infection has been successfully eradicated.

The monitoring phase is crucial to determine the effectiveness of the treatment and to identify any signs of infection re-occurrence.

If the infection re-occurs, a re-treatment with doxycycline is administered. This step ensures that any remaining infection is addressed promptly.

The re-treatment phase follows the same administration guidelines as the initial treatment, with adjustments made as necessary based on the patient’s condition and response.

Throughout the trial, regular follow-up appointments are scheduled to assess the patient’s overall health and the progression of the Ocular Adnexal Marginal Zone Lymphoma (OAMZL).

The primary goal is to achieve a 2-year progression-free survival, meaning the disease does not worsen during this period. Secondary assessments include evaluating the feasibility and tolerability of the treatment, as well as monitoring overall survival and infection eradication rates.